Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290950 | 0.83 | LMNA (0.43) | LMNAKDM4EMEN1KMT2ACYP2C19 | |
| SCHEMBL23023324 | 0.82 | LMNA (0.47) | LMNAKDM4EMEN1KMT2ACYP2C19 | |
| SCHEMBL21844000 | 0.81 | KDM4E (0.54) | LMNAKDM4EGPR119ALDH1A1POLB | |
| SCHEMBL725763 | 0.80 | KDM4E (0.51) | LMNAKDM4EMEN1KMT2ACYP2C19 | |
| SCHEMBL18531953 | 0.80 | ACACB (0.43) | LMNAGPR119TSHR | |
| Hydrochloric Acid SCHEMBL8695078 | 0.79 | KDM4E (0.50) | LMNAKDM4EMEN1KMT2ACYP2C19 | |
| SCHEMBL30549507 | 0.79 | GLS (0.45) | — | |
| SCHEMBL23005918 | 0.77 | KDM4E (0.49) | LMNAKDM4EMEN1KMT2ACYP2C19 | |
| SCHEMBL2603213 | 0.77 | ACHE (0.55) | LMNAKDM4EKMT2ACYP2C19GPR119 | |
| SCHEMBL19652277 | 0.76 | MEN1 (0.55) | LMNAKDM4EMEN1KMT2ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566001-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11014881-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| WO-2021031952-A1 | OXYGEN-SUBSTITUTED SIX-MEMBERED RING PYRIMIDINE COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2021-02-25 | — | — | WO | disclosed |
| US-20200123105-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | SPRING MILL PHARMA, INC. | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123105-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | LMNA 2483/4885KDM4E 3751/4885MEN1 4740/4885 |
| US-11566001-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | LMNA 2483/4885KDM4E 3751/4885MEN1 4740/4885 |
| US-11014881-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | LMNA 2483/4885KDM4E 3751/4885MEN1 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.